These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7302906)

  • 1. Inhibition of the availability of platelet factor 3 by increased concentration of lecithin in platelets caused by gonadal steroids.
    Lillienberg L; Korsan-Bengtsen K; Olausson M; Svanborg A
    Thromb Res; 1981 Jun 1-25; 22(5-6):579-91. PubMed ID: 7302906
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of platelet factor 3 availability by prostacyclin.
    Hársfalvi J; Muszbek L; Stadler I; Fésüs L
    Prostaglandins; 1980 Nov; 20(5):935-45. PubMed ID: 7008092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Blood platelet proteases and their role in platelet protein degradation and platelet coagulation factor inactivation].
    Ostrowska H; Worowski K
    Acta Haematol Pol; 1981; 12(1):17-21. PubMed ID: 7032177
    [No Abstract]   [Full Text] [Related]  

  • 4. Differentiation of factor V-like coagulant activity from catalytic phospholipid-like surface activity in membrane fractions derived from human platelets.
    Dombrose FA; Bode AP; Lentz BR
    Thromb Res; 1981 Jun 1-25; 22(5-6):603-21. PubMed ID: 6895424
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelet membrane involvement in blood coagulation.
    Hemker HC; van Rijn JL; Rosing J; van Dieijen G; Bevers EM; Zwaal RF
    Blood Cells; 1983; 9(2):303-17. PubMed ID: 6661560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation.
    Bode AP; Sandberg H; Dombrose FA; Lentz BR
    Thromb Res; 1985 Jul; 39(1):49-61. PubMed ID: 3839943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of phenylbutazone, naproxen and flunixin meglumine on equine platelet aggregation and platelet factor 3 availability in vitro.
    Johnstone IB
    Can J Comp Med; 1983 Apr; 47(2):172-9. PubMed ID: 6883184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of coagulant activity in human platelets: release of membranous vesicles providing platelet factor 1 and platelet factor 3.
    Sandberg H; Bode AP; Dombrose FA; Hoechli M; Lentz BR
    Thromb Res; 1985 Jul; 39(1):63-79. PubMed ID: 3839944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet factor 3-A time (PF3-A time) in uraemia.
    Dhar JM; Rizvi SN; Rani S; Goel RG; Gulati PD
    Indian J Med Res; 1981 Apr; 73():571-6. PubMed ID: 7262929
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms involved in platelet procoagulant response.
    Bevers EM; Comfurius P; Zwaal RF
    Adv Exp Med Biol; 1993; 344():195-207. PubMed ID: 8209788
    [No Abstract]   [Full Text] [Related]  

  • 11. Procoagulant activity of platelets.
    Kardinal CG; Wegener LT; Anderson LK; Wallin JD
    Arch Pathol; 1975 Aug; 99(8):449-51. PubMed ID: 1147840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifications of platelet functions by dietary fats.
    Renaud S
    Adv Exp Med Biol; 1975; 63():265-76. PubMed ID: 1199867
    [No Abstract]   [Full Text] [Related]  

  • 13. [Thrombocytic step of blood coagulation in rheumatism].
    Gritsiuk AI; Rogozhkina VF
    Ter Arkh; 1980; 52(11):113-8. PubMed ID: 7466637
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of inhibitor of glucose utilization on the blood platelet function.
    Tison P; Kubisz P; Cernácek P; Dzúrik R
    Nephron; 1983; 33(4):253-6. PubMed ID: 6843756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet factor 3 assay and the availability of platelet factor 3 in collagen or thrombin stimulated platelets.
    Brox JH; Osterud B
    Thromb Res; 1984 Mar; 33(5):555. PubMed ID: 6719401
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of halofenate--free acid on aggregation--the release reaction, coagulant activity, and lipid metabolism of human platelets.
    Huzoor-Akbar ; Ardlie NG
    Thromb Haemost; 1977 Oct; 38(3):612-9. PubMed ID: 579507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanisms of action of anti-platelet agents].
    Carreras LO
    Sangre (Barc); 1988 Dec; 33(6):505-21. PubMed ID: 3073536
    [No Abstract]   [Full Text] [Related]  

  • 18. The platelet membrane as a catalytic surface in thrombin generation: availability of platelet factor 1 and platelet factor 3.
    Bode AP; Dombrose FA; Lentz BR; Roberts HR
    Ann N Y Acad Sci; 1981; 370():348-58. PubMed ID: 6943964
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet factor 3 availability induced by phorbol-12-myristate-13-acetate.
    Jerushalmy Z; Englender T; Shaklai M
    Thromb Haemost; 1984 Oct; 52(2):218. PubMed ID: 6523439
    [No Abstract]   [Full Text] [Related]  

  • 20. [Present-day views on the role of blood platelets in hemostasis. II. Role of platelets in plasma clotting].
    Dmoszyńska-Giannopoluou A; Kowalewski J
    Pol Arch Med Wewn; 1978 Aug; 60(2):175-8. PubMed ID: 362384
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.